Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 25:13:558.
doi: 10.1186/1471-2407-13-558.

St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial

Anna-Karin Falck  1 , Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén
Affiliations

St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial

Anna-Karin Falck et al. BMC Cancer. .

Abstract

Background: The St Gallen surrogate molecular subtype definitions classify the oestrogen (ER) positive breast cancer into the luminal A and luminal B subtypes according to proliferation rate and/or expression of human epidermal growth factor receptor 2 (HER2) with differences in prognosis and chemo-responsiveness. Primary tumours and lymph node metastases might represent different malignant clones, but in the clinical setting only the biomarker profile of the primary tumour is used for selection of adjuvant systemic treatment. The present study aimed to classify primary breast tumours and matched lymph node metastases into luminal A, luminal B, HER2-positive and triple-negative subtypes and compare the distributions.

Methods: Eighty-five patients with available tumour tissue from both locations were classified. The distribution of molecular subtypes in primary tumours and corresponding lymph node metastases were compared, and related to 5-year distant disease-free survival (DDFS).

Results: The St Gallen molecular subtypes were discordant between primary tumours and matched lymph node metastases in 11% of the patients (p = 0.06). The luminal A subtype in the primary tumour shifted to a subtype with a worse prognostic profile in the lymph node metastases in 7 of 45 cases (16%) whereas no shift in the opposite direction was observed (0/38) (p = 0.02). All subtypes had an increased hazard for developing distant metastasis during the first 5 years after diagnosis in both primary breast tumours and matched lymph node metastases, compared with the luminal A subtype.

Conclusion: The classification according to the St Gallen molecular subtypes in primary tumours and matched lymph node metastases, implicates a shift to a more aggressive subtype in synchronous lymph node metastases compared to the primary breast tumour. The selection of systemic adjuvant therapy might benefit from taking the molecular subtypes in the metastatic node into account.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distant disease-free survival (DDFS) and overall survival (OS) by St Gallen molecular subtypes in primary tumours. A. Distant disease-free survival (DDFS) by St Gallen molecular subtypes in primary tumours. B. Overall survival (OS) by St Gallen molecular subtypes in primary tumours.
Figure 2
Figure 2
Distant disease-free survival (DDFS) and overall survival (OS) by St Gallen molecular subtypes in matched lymph node metastases. A. Distant disease-free survival (DDFS) by St Gallen molecular subtypes in matched lymph node metastases. B. Overall survival (OS) by St Gallen molecular subtypes in matched lymph node metastases.
Figure 3
Figure 3
Flow chart of study cohort. Abbreviations: ER = Oestrogen receptor, PR = Progesterone receptor, HER2 = Human epidermal growth factor receptor 2, TMA = Tissue microarray.
See this image and copyright information in PMC

References

    1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–1329. doi: 10.1093/annonc/mdp322. - DOI - PMC - PubMed
    1. EBCTCG EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. - PubMed
    1. Joensuu H, Pylkkanen L, Toikkanen S. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. Br J Cancer. 1998;78(6):795–799. doi: 10.1038/bjc.1998.581. - DOI - PMC - PubMed
    1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA. et al.Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS. et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed

Publication types

MeSH terms